Results of a phase 2 trial in patients with Friedreich’s ataxia leaves hope for the future, with regulatory submission on the agenda.
Marco Meglio
Advertisement
Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at [email protected]
Articles by Marco Meglio
Advertisement
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
New 3-Year EMBARK Data Highlights Continued Therapeutic Effect of Gene Therapy Elevidys in Duchenne
2
FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials
3
Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial
4
Priority Review Granted for Weekly Subcutaneous Lecanemab Dosing in Early Alzheimer Disease
5